AKT1 and neoplasm: In mouse models of Tp53 deficiency, genetic loss of Prl2 or pharmacologic inhibition of PRL2 led to PTEN augmentation and attenuation of Akt signaling, which ultimately inhibited tumor cell proliferation to prevent tumor growth and promote survival in these tumor models.